Literature DB >> 11751135

Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

M L Peterson1, L B Hovde, D H Wright, G H Brown, A D Hoang, J C Rotschafer.   

Abstract

An in vitro pharmacodynamic investigation was conducted to explore whether the area under the concentration time curve from 0 to 24 h (AUC(0-24))/MIC ratio could predict fluoroquinolone performance against Bacteroides fragilis. An in vitro model was used to generate kill curves for trovafloxacin (TVA) and levofloxacin (LVX) at AUC(0-24)/MIC ratios of 1 to 406 against three strains of B. fragilis (ATCC 25285, ATCC 23745, and clinical isolate M97-117). TVA and LVX were bolused prior to the start of experiments to achieve the corresponding AUC(0-24)/MIC ratio. Experiments were performed in duplicate over 24 h and in an anaerobic environment. Analyses of antimicrobial performance were conducted by comparing the rates of bacterial kill (K) using nonlinear regression analysis with 95% confidence intervals. Statistical significance was defined as a lack of overlap in the 95% confidence limits generated from the slope of each kill curve. For both TVA and LVX, K was maximized once an AUC(0-24)/MIC ratio of > or =40 was achieved and was not further increased despite a 10-fold increase in AUC(0-24)/MIC from approximately 40 to 400 against all three strains of B. fragilis. No significant differences were found in K between AUC(0-24)/MIC ratios of approximately 40 to 200. In experiments where AUC(0-24)/MIC ratios that were > or = 5 and < or = 44 were conducted, 64% demonstrated regrowth at 24 h. Resistant strains were selected in 50% of those experiments, demonstrating regrowth, which resulted in increased MICs of two- to 16-fold for both TVA and LVX. Regrowth did not occur, nor were resistant strains selected in any studies with an AUC/MIC that was > 44. Our findings suggest that fluoroquinolones provide antibacterial effects against B. fragilis in a concentration-independent manner associated with an AUC(0-24)/MIC ratio of > or =40. Also, the potential for the selection of resistant strains of B. fragilis may increase with an AUC(0-24)/MIC ratio of < or =44.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751135      PMCID: PMC126996          DOI: 10.1128/AAC.46.1.203-210.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  What have we learned from pharmacokinetic and pharmacodynamic theories?

Authors:  J J Schentag; K K Gilliland; J A Paladino
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

2.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

Review 3.  Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design.

Authors:  S C Ebert; W A Craig
Journal:  Infect Control Hosp Epidemiol       Date:  1990-06       Impact factor: 3.254

4.  Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.

Authors:  G H Ross; D H Wright; L B Hovde; M L Peterson; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors:  K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

Authors:  D Milatovic; F J Schmitz; S Brisse; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone.

Authors:  H Oh; C E Nord; L Barkholt; M Hedberg; C Edlund
Journal:  Infection       Date:  2000-09       Impact factor: 3.553

Review 8.  Wound and intraabdominal infections: microbiological considerations and approaches to treatment.

Authors:  R L Nichols; J W Smith
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

9.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  5 in total

1.  Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.

Authors:  Vito Ricci; Marnie L Peterson; John C Rotschafer; Hannah Wexler; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

3.  In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Y Lubenko; Karl Drlica; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; Kelly A Sprandel; Keith A Rodvold; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.

Authors:  Gary E Stein; Sharon Schooley; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.